 |
|
|
 |
Join hundreds of fellow interventional oncologists, radiologists, and experts from around the globe for the premier scientific program packed with cutting edge research, expert-led discussions, and innovative hands-on learning. The SIO 2019 Annual Meeting, taking place 8–11 June 2019, in Boston, offers dynamic, can’t-miss programming, including:
SIO GAME NIGHT
Participate in an evening of food, fun, and not-safe-for-work jeering as IO leaders go head-to-head during hands-on competitions. This interactive session will feature trivia, clinically-relevant demonstrations and friendly competition, featuring:
Visit the SIO 2019 Annual Meeting program website to view the full scientific schedule, view descriptions, sort by date, title, speaker, or course type, view the faculty, and more!
 |
|
OsteoCool™ indications have expanded! Learn more about treatment options for patients with painful bone metastases and benign bone tumors, such as osteoid osteoma. Learn about OsteoCool™.
Learn about OsteoCool™. |
|
On 7 June, learn from international experts as they lead this full-day course of didactic lectures and hands-on, image-guided practice on specially-constructed simulation models. This how-to course will cover everything from biopsy approach to vertebral augmentation – and will include the first-ever formal training in pelvic screw fixation specifically designed for the interventional radiologist.
The field of Interventional Oncology, as well as the continued success of Society of Interventional Oncology (SIO), is dependent on individuals like you. SIO membership not only illustrates dedication to the mission of the society, but to the continued growth and success of the field of IO. Your membership secures your place among the most influential minds in this emerging specialty and gives you access to New Member Benefits!
AND… Did you know that bundling membership to SIO with SIO 2019 registration costs much less than just attending the meeting?
See for yourself how taking advantage of new SIO 2019 registration bundles ultimately covers the cost of an SIO membership!
|
| Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year. Read more |
|
|
|
|
|
|
SIO 2020 is moving to a new date and location:
31 January–3 February 2020 | New Orleans, Louisiana, USA 
Respiration
Standard therapy for cancer-associated venous thromboembolism (VTE) is low-molecular-weight heparin. The use of direct oral anticoagulants for cancer-associated VTE has increased; however, their efficacy and safety in lung cancer patients remain unclear. This study examined the efficacy and safety of rivaroxaban compared with dalteparin for cancer-associated VTE in patients with primary lung cancer. READ MORE
Journal of Contemporary Brachytherapy
This study sought a curative technique to treat recurrent or primary nonsmall cell lung cancer (NSCLC) with a minimally invasive outpatient technique that could be repeated multiple times, had minimal pulmonary toxicity and was readily available in the community setting. Percutaneous outpatient computed tomography (CT) fluoroscopy-guided permanent seed brachytherapy fits these criteria. READ MORE
Radiology
Patients with recurrent intermediate-stage hepatocellular carcinoma and microvascular invasion–positive status benefit from longer survival times by using a combined treatment of sorafenib with transarterial chemoembolization (TACE) compared with TACE alone. The evidence of combining sorafenib with transarterial chemoembolization (TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient responses to this treatment varied because of the heterogeneous nature of intermediate-stage recurrent HCC, making it important to identify patients who are most likely to benefit from this combination therapy. READ MORE
BMC Medicine
Nonalcoholic fatty liver disease (NAFLD) is a common condition that progresses in some patients to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. This study used healthcare records of 18 million adults to estimate risk of acquiring advanced liver disease diagnoses in patients with NAFLD or NASH compared to individually matched controls. READ MORE
Cancer Letters
This study evaluated the biological functions associated with IR-A overexpression in HCC in relation to expression of its ligand IGF-II. The value of INSRA:INSRB ratio which was increased in ˜70% of 85 HCC was associated with stem/progenitor cell features such as cytokeratin-19 and α-fetoprotein and correlated with shorter patient survival. IGF2 mRNA upregulation was observed in 9.4% of HCC and was not associated with higher INSRA:INSRB ratios. READ MORE
Clinical and Molecular Hepatology
Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma, but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems. READ MORE |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
